브라질에서 팔보시클립을 받는 HR+/HER2- 진행성/전이성 유방암 환자의 패턴 및 결과

Simon 등(목요일)이 이 질문을 연구하였다.

www.synapsesocial.com/papers/68e59453b6db64358752fbe9 — DOI: https://doi.org/10.1080/14796694.2024.2388022

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Real-world treatment patterns and clinical outcomes among patients with HR+/HER2- advanced/metastatic breast cancer receiving palbociclib in Brazil: IRIS study.· 2024 · 1 citations
2. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study· 2014 · 1,906 citations
3. Cancer mortality predictions for 2017 in Latin America· 2017 · 49 citations
4. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance· 2017 · 43 citations
5. ESMO Guidance for Reporting Oncology real-World evidence (GROW)· 2023 · 201 citations